291 related articles for article (PubMed ID: 23086587)
1. Modelling the cost-effectiveness of pregabalin versus usual care in daily practice in the treatment of refractory generalised anxiety disorder in Spain.
De Salas-Cansado M; Álvarez E; Olivares JM; Carrasco JL; Ferro MB; Rejas J
Soc Psychiatry Psychiatr Epidemiol; 2013 Jun; 48(6):985-96. PubMed ID: 23086587
[TBL] [Abstract][Full Text] [Related]
2. Pregabalin versus SSRIs and SNRIs in benzodiazepine-refractory outpatients with generalized anxiety disorder: a post hoc cost-effectiveness analysis in usual medical practice in Spain.
De Salas-Cansado M; Olivares JM; Alvarez E; Carrasco JL; Barrueta A; Rejas J
Clinicoecon Outcomes Res; 2012; 4():157-68. PubMed ID: 22745564
[TBL] [Abstract][Full Text] [Related]
3. An economic evaluation of pregabalin versus usual care in the management of community-treated patients with refractory painful diabetic peripheral neuropathy in primary care settings.
de Salas-Cansado M; Pérez C; Saldaña MT; Navarro A; González-Gómez FJ; Ruiz L; Rejas J
Prim Care Diabetes; 2012 Dec; 6(4):303-12. PubMed ID: 22595032
[TBL] [Abstract][Full Text] [Related]
4. A cost-effectiveness analysis of the effect of pregabalin versus usual care in the treatment of refractory neuropathic pain in routine medical practice in Spain.
de Salas-Cansado M; Pérez C; Saldaña MT; Navarro A; Rejas J
Pain Med; 2012 May; 13(5):699-710. PubMed ID: 22594706
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of pregabalin versus venlafaxine in the treatment of generalized anxiety disorder: findings from a Spanish perspective.
Vera-Llonch M; Dukes E; Rejas J; Sofrygin O; Mychaskiw M; Oster G
Eur J Health Econ; 2010 Feb; 11(1):35-44. PubMed ID: 19506926
[TBL] [Abstract][Full Text] [Related]
6. A comparative cost-analysis of initiating pregabalin or SSRI/SNRI therapy in benzodiazepine-resistant patients with generalized anxiety disorder in Spain.
Carrasco JL; Álvarez E; Olivares JM; Rejas J
Actas Esp Psiquiatr; 2013; 41(3):164-74. PubMed ID: 23803800
[TBL] [Abstract][Full Text] [Related]
7. Cost-utility of cognitive behavioral therapy versus U.S. Food and Drug Administration recommended drugs and usual care in the treatment of patients with fibromyalgia: an economic evaluation alongside a 6-month randomized controlled trial.
Luciano JV; D'Amico F; Cerdà-Lafont M; Peñarrubia-María MT; Knapp M; Cuesta-Vargas AI; Serrano-Blanco A; García-Campayo J
Arthritis Res Ther; 2014 Oct; 16(5):451. PubMed ID: 25270426
[TBL] [Abstract][Full Text] [Related]
8. Clinical and economic outcomes of adjunctive therapy with pregabalin or usual care in generalized anxiety disorder patients with partial response to selective serotonin reuptake inhibitors.
Álvarez E; Olivares JM; Carrasco JL; López-Gómez V; Rejas J
Ann Gen Psychiatry; 2015; 14(1):2. PubMed ID: 25632294
[TBL] [Abstract][Full Text] [Related]
9. A cost-consequences analysis of the effect of pregabalin in the treatment of peripheral neuropathic pain in routine medical practice in primary care settings.
Navarro A; Saldaña MT; Pérez C; Torrades S; Rejas J
BMC Neurol; 2011 Jan; 11():7. PubMed ID: 21251268
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness analysis of a lidocaine 5% medicated plaster compared with gabapentin and pregabalin for treating postherpetic neuralgia: a german perspective.
Liedgens H; Hertel N; Gabriel A; Nuijten M; Dakin H; Mitchell S; Nautrup BP
Clin Drug Investig; 2008; 28(9):583-601. PubMed ID: 18666805
[TBL] [Abstract][Full Text] [Related]
11. Pharmacoeconomic outcomes for pregabalin: a systematic review in neuropathic pain, generalized anxiety disorder, and epilepsy from a Spanish perspective.
Darbà J; Kaskens L; Pérez C; Álvarez E; Navarro-Artieda R; Sicras-Mainar A
Adv Ther; 2014 Jan; 31(1):1-29. PubMed ID: 24390901
[TBL] [Abstract][Full Text] [Related]
12. Cost effectiveness of a lidocaine 5% medicated plaster compared with pregabalin for the treatment of postherpetic neuralgia in the UK: a Markov model analysis.
Ritchie M; Liedgens H; Nuijten M
Clin Drug Investig; 2010; 30(2):71-87. PubMed ID: 20067326
[TBL] [Abstract][Full Text] [Related]
13. Cost-utility of pregabalin as add-on to usual care versus usual care alone in the management of peripheral neuropathic pain in Belgium.
Chevalier P; Lamotte M; Van Campenhout H; Eyckerman R; Annemans L
J Med Econ; 2013; 16(5):596-605. PubMed ID: 23409950
[TBL] [Abstract][Full Text] [Related]
14. The cost of generalized anxiety disorder in primary care settings: results of the ANCORA study.
Rovira J; Albarracin G; Salvador L; Rejas J; Sánchez-Iriso E; Cabasés JM
Community Ment Health J; 2012 Jun; 48(3):372-83. PubMed ID: 22484993
[TBL] [Abstract][Full Text] [Related]
15. [Analysis of the cost-effectiveness of treatment for refractory partial epilepsy: a simulation model for pregabalin and levetiracetam].
Díaz S; Argumosa A; Horga de la Parte JF; Vera-Llonch M; Dukes E; Rejas-Gutiérrez J
Rev Neurol; 2007 Oct 16-31; 45(8):460-7. PubMed ID: 17948211
[TBL] [Abstract][Full Text] [Related]
16. A cost-utility study of the use of pregabalin in treatment-refractory neuropathic pain.
Gordon J; Lister S; Prettyjohns M; McEwan P; Tetlow A; Gabriel Z
J Med Econ; 2012; 15(2):207-18. PubMed ID: 22017236
[TBL] [Abstract][Full Text] [Related]
17. Costs and health resources utilization following switching to pregabalin in individuals with gabapentin-refractory neuropathic pain: a post hoc analysis.
Navarro A; Saldaña MT; Pérez C; Masramón X; Rejas J
Pain Pract; 2012 Jun; 12(5):382-93. PubMed ID: 22004531
[TBL] [Abstract][Full Text] [Related]
18. Psychotherapy for Major Depressive Disorder and Generalized Anxiety Disorder: A Health Technology Assessment.
Health Quality Ontario
Ont Health Technol Assess Ser; 2017; 17(15):1-167. PubMed ID: 29213344
[TBL] [Abstract][Full Text] [Related]
19. Cost effectiveness of pregabalin in the treatment of fibromyalgia from a UK perspective.
Choy E; Richards S; Bowrin K; Watson P; Lloyd A; Sadosky A; Zlateva G
Curr Med Res Opin; 2010 Apr; 26(4):965-75. PubMed ID: 20178405
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness analysis of pregabalin versus gabapentin in the management of neuropathic pain due to diabetic polyneuropathy or post-herpetic neuralgia.
Rodríguez MJ; Díaz S; Vera-Llonch M; Dukes E; Rejas J
Curr Med Res Opin; 2007 Oct; 23(10):2585-96. PubMed ID: 17875242
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
